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OBJECTIVES We investigated the in situ properties of muscle mitochondria using the skinned fiber
technique in patients with chronic heart failure (CHF) and sedentary (SED) and more active
(ACT) controls to determine: 1) whether respiration of muscle tissue in the SED and ACT
groups correlates with peak oxygen consumption (pVO2), 2) whether it is altered in CHF, and
3) whether this results from deconditioning or CHF-specific myopathy.
BACKGROUND Skeletal muscle oxidative capacity is thought to partly determine the exercise capacity in
humans and its decrease to participate in exercise limitation in CHF.
METHODS M. Vastus lateralis biopsies were obtained from 11 SED group members, 10 ACT group
members and 15 patients with CHF at the time of transplantation, saponine-skinned and
placed in an oxygraphic chamber to measure basal and maximal adenosine diphosphate
(ADP)-stimulated (Vmax) respiration rates and to assess mitochondrial regulation by ADP.
All patients received angiotensin-converting enzyme (ACE) inhibitors.
RESULTS The pVO2 differed in the order CHF , SED , ACT. Compared with SED, muscle
alterations in CHF appeared as decreased citrate synthase, creatine kinase and lactate
dehydrogenase, whereas the myosin heavy chain profile remained unchanged. However,
muscle oxidative capacity (Vmax, CHF: 3.53 6 0.38; SED: 3.17 6 0.48; ACT: 7.47 6 0.73,
mmol O2zmin
21zg21dw, p , 0.001 vs. CHF and SED) and regulation were identical in
patients in the CHF and SED groups, differing in the ACT group only. In patients with
CHF, the correlation between pVO2 and muscle oxidative capacity observed in controls was
displaced toward lower pVO2 values.
CONCLUSIONS In these patients, the disease-specific muscle metabolic impairments derive mostly from
extramitochondrial mechanisms that disrupt the normal symmorphosis relations. The
possible roles of ACE inhibitors and level of activity are discussed. (J Am Coll Cardiol 2001;
38:947–54) © 2001 by the American College of Cardiology
Factors limiting maximal oxygen consumption (VO2) during
exercise in humans involve both central and peripheral
factors. Among the latter, oxidative enzymes or mitochon-
drial density of vastus lateralis muscle have been shown to
correlate with exercise capacity (1). Chronic heart failure
(CHF) is characterized by an increasingly severe exertional
handicap that does not correlate with the degree of ventric-
ular dysfunction but represents one of the best predictors of
mortality (2). It is commonly accepted that an abnormal
muscle metabolism, partly unrelated to oxygen supply,
contributes to the exercise impairment (2–4). A comparison
with controls suggests that the increased lactate production
(5), the increased phosphocreatine breakdown and intracel-
lular acidosis (4) and the decreased rate of ATP resynthesis
(2,4) result from abnormalities at the mitochondrial level.
This is supported by the observation of a diminished
mitochondrial density (1) and activity of selected oxidative
enzymes (6,7) and by a recent report of our group showing
decreased skeletal muscle oxidative capacity and mitochon-
drial regulation in a rat model of CHF (8). However, the
intrinsic mitochondrial function has never been directly
assessed in patients with CHF. Mechanisms upstream of
mitochondria also contribute to the patient’s exertional
handicap. A diminished muscle blood flow (5), an altered
pattern of fiber recruitment (9), an increased production of
tissue nitric oxide (NO) by the inducible NO synthase (10),
and a decreased muscular capillary density (1,11) have all
been suggested to participate in CHF exercise intolerance.
Moreover, since previous studies did not always include a
truly sedentary control group, they may have attributed to
CHF changes that may have resulted from deconditioning
only (11).
The aim of this study was, thus, to compare the intrinsic
mitochondrial function, enzymatic equipment and myosin
heavy chain (MHC) profile of biopsy samples from the
vastus lateralis muscle in patients with CHF to those of
truly sedentary (SED) or more active (ACT) controls. As
selective permeabilization of cellular membranes offers the
unique opportunity to study in situ the oxidative capacity of
muscle cells and the mitochondrial regulatory properties, we
adapted to human samples the oxygraphic respiration as-
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sessment of skinned muscle fibers, which has previously
been validated in animals (12).
METHODS
Subjects and exercise testing. Fifteen consecutive New
York Heart Association class III patients with CHF were
included in the study at the time of heart transplantation.
Their characteristics are given in Table 1. Causes of heart
failure were dilated idiopathic cardiomyopathy in nine
patients, ischemic heart disease in four patients, congenital
heart disease in one patient and valvular disease in one
patient. Their peak VO2 was 13.2 mlzmin
21zkg21 6 0.6
mlzmin21zkg21. All patients received diuretics and
angiotensin-converting enzyme (ACE) inhibitors. These
patients’ exercise and muscle biopsy parameters were com-
pared with those of 11 SED and 10 ACT controls who
volunteered for the study (Table 1). We classified our
volunteers as SED if their peak VO2 was, at most, equal to
110% of the predicted normal maximal VO2 (VO2max)
according to Wasserman’s formulas (13) and as ACT if
their peak VO2 was over 110% of predicted. All subjects gave
their informed consent to participate in the study that had
been approved by our institution’s ethics committee and
underwent a cycloergometric incremental symptom-limited
exercise test while measuring the VO2 and the carbon
dioxide produced (VCO2) by means of a metabolic cart
(Medical Graphics, St. Paul, Minnesota). In CHF patients,
exercise tests (10 Wzmin21) were repeated every three
months to assess urgency, the last pretransplantation values
being taken for this study. In controls, the exercise test
increments were designed (15 Wzmin21 to 25 Wzmin21) to
exhaust the subject in 10 min to 15 min and took place
within two weeks of their biopsy. The aerobic-anaerobic
transition was determined by the ventilatory threshold
(VT) defined by V-slope analysis (13). These tests yielded
the rest, VT and peak VO2, respiratory exchange ratio
([RER] 5 VCO2/VO2) and HR.
Skeletal muscle biopsy. M. Vastus lateralis tissue was
taken by the Bergstro¨m biopsy technique under general
anesthesia in patients and local anesthesia in controls. One
part was immediately frozen in liquid nitrogen for enzy-
matic and isomyosin studies. Thin bundles (diameter:
100 mm to 200 mm) were immediately dissected as previ-
ously described (14) in iced relaxing solution containing
(in mM) EGTA-calcium buffer 10 (free Ca21 concentra-
tion 100 nM), MgCl2 1, taurine 20, DTT 0.5, imidazole 20
(pH 7.1), MgATP 5, PCr 15, at ionic strength 160
(potassium methanesulfonate) and permeabilized for 30 min
with 50 mgzml21 saponin for respiration studies.
Mitochondrial respiration. Respiratory parameters of the
total mitochondrial population were studied in situ as
previously described (12,14) using a Clark electrode (Strath-
kelvin Instruments, Glasgow, Scotland) in a water-jacketed
oxygraphic cell containing 3 ml of respiration solution (see
subsequent text) at 22°C with continuous stirring. Respira-
tion rates were expressed as mmol O2zmin
21zg21 dry weight.
Respiration solution had the same composition as the
relaxing solution except that MgATP and PCr were re-
placed by 5 mM glutamate, 2 mM malate as substrates and
3 mM phosphate and 2mgzml21 fatty acid free bovine serum
albumin. The adenosine diphosphate (ADP)-stimulated
respiration (VADP) above basal oxygen consumption was
plotted as a function of ADP with and without creatine
(20 mM). The apparent Km for ADP and VADP were
calculated using a nonlinear fitting of the Michaelis-Menten
equation. Maximal respiration rate (Vmax) is (VADP 1 basal
oxygen consumption). The acceptor control ratio (ACR) is
Vmax/basal oxygen consumption. As an example, mitochon-
drial oxygen consumption in function of ADP concentra-
tion (raw data) and the fitting procedure for a representative
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ACR 5 acceptor control ratio
ACT 5 active normal controls
ADP 5 adenosine diphosphate
CHF 5 chronic heart failure
CK 5 creatine kinase
CS 5 citrate synthase
HR 5 heart rate
LDH 5 lactate dehydrogenase
MHC 5 myosin heavy chain
NO 5 nitric oxide
RER 5 respiratory exchange ratio
SED 5 true sedentary controls
VADP 5 ADP-stimulated tissue oxygen uptake
VCO2 5 carbon dioxide produced
Vmax 5 maximal tissue oxygen uptake
VO2max 5 predicted normal maximal oxygen uptake
VO2 5 oxygen uptake
VT 5 ventilatory threshold
Table 1. Group Characteristics
Patients
With CHF
Sedentary
Controls
Active
Controls p (ANOVA)
Men/Women 13/2 10/1 8/2 —
Age (yrs) 52.8 6 2.3 51.2 6 2.6 46.9 6 1.9 0.194
Weight (kg) 73.3 6 3.0† 87.2 6 4.1 71.5 6 2.7* 0.005
Height (cm) 171 6 2 176 6 3 172 6 2 0.208
Peak VO2 (% of predicted) 41 6 3‡§ 93 6 4 132 6 4‡ , 0.0001
Values 5 means 6 SEM. *p # 0.05; †p # 0.01; ‡p # 0.001 vs. sedentary controls; §p # 0.001 vs. active controls.
ANOVA 5 analysis of variance; CHF 5 chronic heart failure; Peak VO2 5 peak oxygen uptake as percentage of the predicted
maximum oxygen uptake for normal sedentary subjects (13).
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subject with CHF and an ACT subject are shown in
Figure 1.
Enzyme analysis. Part of the frozen tissue samples were
weighed, homogenized into cold buffer (30 mgzmL21)
containing (in mM): HEPES 5 (pH 8.7), EGTA 1, MgCl2
5 and Triton X-100 (0.1%) and incubated for 60 min at 0°C
to ensure complete enzyme extraction. Creatine kinase (CK)
and lactate dehydrogenase (LDH) were assayed (30°C,
pH 7.5) using a coupled enzyme system as previously
described (15). Creatine kinase and LDH isoenzymes were
separated using agarose gel (1%) electrophoresis performed
at 200 V for 90 min. Individual isoenzymes were resolved
either by incubating the gels with a coupled enzyme system
(CK) or a commercial revelation system (Sigma LDH
reagent kit, Saint Quentin, France) followed by image
analysis.
MHC. In the remaining frozen tissue, myosin was crudely
extracted in a high ionic strength buffer as previously described
(15). The MHCs were separated in 8% acrylamide-bis (50:1)
slab gels at constant voltage (70 V) for 28 h and stained with
Coomassie blue, then scanned by laser densitometry (Ultroscan
XL, Turku, Finland).
Statistical analysis. The values are expressed as means 6
SEM. We used one-way analysis of variance (ANOVA)
followed by a Student-Neumann-Keuls postprocedure to
compare the CHF, SED and ACT groups. A two-way
ANOVA was used to determine statistical differences in
HR and respiratory metabolic data (subject group, level of
exercise). When appropriate, differences between groups
were tested with a Newman-Keuls post hoc test. Within
each group the comparison of the Km with and without
creatine were performed by a paired t test. Significance was
taken as p # 0.05.
RESULTS
Exercise studies. By design, the VO2 to weight ratio were
all very different among groups (13.2 6 0.6 mlzmin21zkg21;
Figure 1. Examples of the Michaelis-Menten kinetics of the oxygen consumption of permeabilized vastus lateralis myofibers to increasing levels of the
phosphate acceptor adenosine diphosphate (ADP). (A) Raw data obtained by myofibers respiration within the oxygraphic chamber from a representative
patient with chronic heart failure (CHF) (upper) and an active control (lower). The tissue O2 consumption (V, mmoles O2zmin
21zg21 dry weight) increases
with increasing doses of the phosphate acceptor ADP. These experiments were performed in the absence (thick line) or in the presence (thin line) of
20 mM creatine. Panel B shows the ADP-related respiration characterizing the Michaelis and Menten kinetics of ADP phosphorylation for the same CHF
(interrupted lines) or active normal controls (ACT) (continuous line) groups as in panel A. The upper part represents the experiments without creatine
and the lower part those with 20 mM creatine. The striking difference in maximal tissue oxygen uptake between the patients with CHF and the active
control group is reflected by the differing asymptotic values of O2 uptake. In CHF, the fast increase in oxygen uptake with ADP reflects the low Km without
creatine (42 mM), which is unchanged with creatine (25 mM). In the active control, the Km is much higher (214 mM) and decreases with creatine (59 mM).
949JACC Vol. 38, No. 4, 2001 Mettauer et al.
October 2001:947–54 Muscle Mitochondrial Function and Heart Failure
27.3 6 1.4 mlzmin21zkg21 and 43.0 6 2.5 mlzmin21zkg21 in
the CHF, SED and ACT groups, respectively, all p ,
0.001), as were the percentages of predicted peak VO2:
,50% of predicted values in patients with CHF, close to
the predicted values in the SED group and 42% higher in
the ACT group than in the SED group. While ages and
heights were similar among groups, the SED group was
heavier than the ACT group and the CHF group (Table 1).
The gas exchanges at rest and during the incremental
symptom-limited exercise are presented in Table 2. A
two-way interaction between subject groups and exercise
level was detected for VO2 (p , 0.001) and HR (p , 0.001).
This means that the changes in these parameters during
exercise were strongly dependent of the subject group.
Although gas exchanges were similar among groups at rest,
the RER was slightly higher in the CHF group. The resting
HR also tended to be higher in patients with CHF, being
significantly higher than that in the ACT controls. At the
VT, most parameters were lower in patients with CHF than
in the SED and ACT groups except for the RER, which
was similar among groups. At peak exercise, all parameters
were clearly lower in patients with CHF except the RER,
which was similar and reached values indicating that all
subjects reasonably approached exhaustion. Most VT and
peak exercise parameters appeared to be higher in the ACT
group than in the SED group according to their differences
in fitness.
Mitochondrial function. The respiratory parameters of
the whole mitochondrial population of muscle biopsies was
directly assessed in fibers after membrane permeabilization
by saponin. Basal respiration of myofibers was similar in the
three groups (1.22 6 0.11 mmol O2zmin
21zg21 dry weight,
1.26 6 0.18 mmol O2zmin
21zg21 dry weight and 1.10 6
0.21 mmol O2zmin
21zg21 dry weight, respectively, in the
CHF, SED and ACT groups, p 5 0.20). Despite the much
lower peak and VT VO2 in patients with CHF, the Vmax of
myofibers, representing the maximal oxidative phosphory-
lation capacity of the mitochondria in the presence of
saturating amounts of ADP, were similar in patients with
CHF and SED controls (Fig. 2), whereas it was two times
higher in the ACT group than in both the SED and CHF
groups. The ACR, representing the degree of coupling
between oxidation and phosphorylation, was also similar in
the CHF and SED groups (2.86 6 0.24 vs. 2.81 6 0.42,
respectively, p 5 NS), whereas it was higher in the ACT
group (5.74 6 0.80, p , 0.001 vs. the SED and CHF
groups, overall p 5 0.0002). Km for ADP was low and did
not change with the addition of creatine in patients with
CHF or in the SED group, whereas it was higher and
diminished with creatine in the ACT group (Fig. 3).
Muscle Vmax was linearly related to the peak VO2 in controls
and in patients but only insignificantly in the latter
because of the narrow range of values (a peak VO2 ,
14 mlzmin21zkg21 being among the selection criteria for
transplantation). Moreover, a strong correlation was also
observed with VO2 at VT, a parameter more closely related
to the endurance capacity (Fig. 4B). The enzymes, their
isoforms and percentages of MHC are presented in Table 3.
The content of the intramitochondrial Krebs cycle enzyme
citrate synthase (CS) was significantly lower in the CHF
group and higher in the ACT group when compared with
the SED group. Total CK and cytosolic MM-CK were
lower in the CHF group only, whereas MB-CK was higher
in the ACT group only. Total LDH activity was also lower
in the CHF group, whereas H-LDH isoform was higher in
the ACT group. The adenylate kinase was similar in all
groups. Finally, no difference in myosin isoforms was
observed in the CHF group compared with the SED group,
while in the ACT group, the percentage of MHC-1 was
higher than it was in the SED group, and MHC-2X was
lower than that in the CHF group.
DISCUSSION
This study is the first direct assessment of skeletal muscle
mitochondrial intrinsic oxidative capacity and regulation in
end-stage CHF, made by means of oxygraphic techniques
in saponin-skinned myofibers. This is also the first deter-
mination of the ADP sensitivity of in situ mitochondria in
patients with CHF and healthy subjects. The main finding
is that oxidative capacity and mitochondrial regulation
clearly differed between sedentary and active controls but
Table 2. Gas Exchanges During the Incremental Exercise Test
Patients With
CHF
Sedentary
Controls
Active
Controls
p
(ANOVA)
Rest VO2 346 6 27 310 6 17 352 6 27 0.479
RER 0.94 6 0.03\ 0.81 6 0.02 0.83 6 0.02 0.0005
HR 88 6 6¶ 77 6 4 71 6 3 0.049
VT VO2 652 6 41‡¶ 1,311 6 87 1,764 6 145† , 0.0001
RER 0.95 6 0.02 0.93 6 0.02 0.93 6 0.01 0.4812
HR 103 6 3†¶ 119 6 4 129 6 4 , 0.0001
Max. Effort VO2 977 6 68¶‡ 2,367 6 107 3,095 6 243† , 0.0001
RER 1.22 6 0.05 1.15 6 0.02 1.22 6 0.02 0.350
HR 124 6 5¶‡ 166 6 6 179 6 3 , 0.0001
Values 5 means 6 SEM; interaction term (two-way ANOVA) for VO2 and HR: p , 0.001. *p # 0.05; †p # 0.01; ‡p # 0.001,
vs. sedentary controls; §p # 0.05; \p # 0.01; ¶p # 0.001, vs. active controls.
ANOVA 5 analysis of variance; CHF 5 chronic heart failure; RER 5 respiratory exchange ration (VCO2/VO2); VO2 5
oxygen uptake (mlzmin21 STPD); HR 5 heart rate (beatszmin21); VT 5 ventilatory threshold.
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that the intrinsic mitochondrial function in our patients
with CHF did not differ from that of truly sedentary
controls.
Skeletal muscle oxidative characteristics. Respiration of
skinned fibers is the unique mean to assess the function of
the whole mitochondrial population within its cellular
environment, with saturating amounts of oxygen and sub-
strates (12). This allows a direct measurement of muscle
oxidative capacity. As expected, this parameter was lower in
the SED group than in the ACT group. However, oxidative
capacity of skeletal muscle of patients with CHF was
identical to that of the SED group, suggesting that the
mitochondrial oxidative phosphorylation pathway is pre-
served in these patients. Moreover, we could demonstrate
that mitochondrial regulation by the phosphate acceptor
ADP or by the mitochondrial CK was identical between the
SED and CHF groups, with both groups greatly differing
from the ACT group. The characteristics of mitochondrial
respiration in the SED and CHF groups are close to those
described for fast-glycolytic muscle of rodents, while those
of the ACT group approach those for the slow-oxidative
muscle, that is, high oxidative capacity, low sensitivity to
external ADP and control of respiration by mitochondrial
CK (12,15,16). These differences suggest a higher oxidative
potential in ACT muscles and are in line with the decreased
sensitivity of mitochondrial respiration to external ADP
with increased physical activity already indirectly evoked by
Tonkonogi et al. (17). The low permeability for ADP of
mitochondria from oxidative muscles has been interpreted
as a means of directly connecting mitochondrial respiration
to the CK shuttle (18). This enables efficient PCr synthesis
at sites of ATP production, fast energy transfer by cytosolic
CK and efficient ATP rephosphorylation by the myosin-
bound CK (16).
Biochemical studies. Despite great variability in patients,
an increase in the relative content of MHC-2X could be
observed from the ACT to SED to CHF groups, consistent
with previous studies (6,19). Earlier studies reported less
slow and higher fast fiber types in patients with CHF (6),
but Vescovo et al. (19) showed that ACE inhibitor treat-
ment normalized their abnormal MHC profile, thus ex-
plaining the insignificant difference in MHC between our
CHF and SED groups. In contrast, enzymes involved in
energy transfer and substrate utilization were specifically
Figure 2. Comparison between exercise capacity and oxidative capacity of vastus lateralis muscle. The maximal adenosine diphosphate (ADP)-stimulated
respiration rate of the saponin-skinned fibers (maximal tissue oxygen uptake [Vmax], mmol O2zmin
21zg21 dry weight tissue, left panel) were identical
between patients with chronic heart failure (CHF) (open bars) and sedentary controls (SED) (hatched bars), both differing from active controls (ACT)
(black bars). The peak oxygen uptake ([VO2 peak] mlzmin
21zkg21, middle panel) and the O2 uptake at the ventilatory threshold ([VO2 at VT]
mlzmin21zkg21, right panel), representing exercise capacity, highly differed among groups in the order CHF , SED , ACT.
Figure 3. Apparent Michaelis-Menten constant without and with creatine for
the adenosine diphosphate (ADP)-stimulated respiration of myofibers. The
apparent Michaelis-Menten constant ([KmADP] mM) of the saponin-skinned
fibers without creatine (hatched bars) were similarly low in patients with
chronic heart failure (CHF) and sedentary controls (SED) and unchanged
with the addition of creatine (black bars). In the active controls (ACT) the
high Km value, which decreases with creatine, shows that the oxygen
consumption is controlled by the mitochondrial creatine kinase.
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diminished in our CHF group (total and MM-CK, total
LDH). This is at first surprising since a higher amount of
these two enzymes is normally present in fast glycolytic and
deconditioned muscles (15). However, this is reminiscent of
what was observed in the failing myocardium of humans
and animals (14,20) and in the oxidative muscle of rats with
CHF (8) and may be a hallmark of CHF. On the other
hand, compared with the SED group, CS activity was lower
in patients with CHF and higher in the ACT group in
accordance with many studies (6,7).
Potential mechanisms for the abnormal skeletal muscle
metabolism in CHF. Taken together, our results of main-
tained oxidative capacity in CHF require three consider-
ations. First, the fact that the concentration or activity of
several enzymes of the Krebs cycle and of certain electron
transport chain complexes like the cytochrome oxidase (21)
have been found lowered in skeletal muscle from patients
with CHF does not imply a decreased overall oxidative
function since mitochondria are functioning well above their
limitation threshold for most of their enzymatic complexes
(22), in line with the cytochrome oxidase excess already
largely documented (23). A limitation at the level of the
Krebs cycle is an unlikely explanation despite the decrease in
CS we and others found (6,24) because neither CS nor the
Krebs cycle are rate-controlling mitochondrial respiration
(22,25). Indeed, numerous extra-mitochondrial reasons also
explain the high-energy phosphate abnormalities in CHF.
High-energy phosphate abnormalities observed in CHF
skeletal muscle may result from intrinsic or extrinsic factors
(1–3,24). The decreased capillary density and endothelium-
dependent vasodilation may cause uneven distribution of
blood flow within the muscle and a decrease in cellular
oxygen and substrate supply (1,11). Moreover, the reduced
muscle mass and the fiber type distribution changes result in
a greater type II fiber recruitment for a given work rate (2,9).
This leads to early intracellular acidosis and excess tissue
NO due to the increased inducible NO synthase and might
contribute to a decreased mitochondrial ATP production,
which is not seen in the respiration chamber (10,26).
Indeed, excess NO has already been demonstrated to
Figure 4. Correlation between exercise capacity and muscle oxidative capacity. (A) The relation between myofibers oxidative capacity and peak oxygen
uptake (VO2 peak) (mlzmin
21zkg21) of patients with chronic heart failure (CHF) (open circles) is shifted leftward from the normal relation in controls
(sedentary subjects: open triangles; active controls: closed triangles). (B) The relation between myofibers oxidative capacity and VO2 (mlzmin
21zkg21) at
ventilatory threshold (VT), taken as an index of endurance capacity, of CHF patients is also shifted leftward from the normal relation in controls (symbols
as in A).
Table 3. Enzymes and MHC
Parameters
Patients With
CHF
Sedentary
Controls
Active
Controls p (ANOVA)
Creatine kinase Total-CK 1,214 6 102‡ 1,937 6 160 1,941 6 108 , 0.0001
MM-CK 1,200 6 100‡¶ 1,912 6 156 1,906 6 107 , 0.0001
MB-CK 8.5 6 2.0\ 16.2 6 3.1 23.7 6 5.3 0.004
mi-CK 6.3 6 1.4 9.6 6 0.8 10.8 6 1.8 0.053
Citrate synthase 9.7 6 0.8‡¶ 16.1 6 1.4 20.0 6 1.2* , 0.0001
Adenylate kinase 283 6 29 289 6 33 259 6 30 0.822
LDH Total LDH 93 6 12* 142 6 12 121 6 16 0.023
H-LDH# 22.6 6 4.4§ 32.2 6 4.4 39.1 6 4.6 0.020
M-LDH# 70 6 10 103 6 13 81 6 13 0.127
H-/M-LDH# 0.37 6 0.06 0.34 6 0.06 0.56 6 0.08 0.214
MHC MHC-1 42.5 6 4.8 36.2 6 6.0 54.6 6 3.4* 0.031
MHC-2A 25.2 6 3.8 37.0 6 4.4 34.2 6 3.0 0.124
MHC-2X 32.3 6 5.6§ 26.0 6 4.6 11.2 6 2.3 0.018
Values 5 means 6 SEM. *p # 0.05; †p # 0.01; ‡p # 0.001, vs. sedentary controls; §p # 0.05; \p # 0.01; ¶p # 0.001, vs. active controls; #H-/M-LDH 5 (H-LDH)/(M-LDH)
with H 5 H4 1 3⁄4H3M 1 1⁄2H2M2 1 1⁄4HM3 and M-LDH 5 M4 1 3⁄4H1M3 1 1⁄2H2M2 1 1⁄4H3M, where H4, M4, H3M, H2M2, HM3 are homo and heterotetramers
of LDH. Enzymatic activities are in IUzg21 wet weight.
CHF 5 chronic heart failure; CK 5 creatine kinase; LDH 5 lactate dehydrogenase; MHC 5 myosin heavy chain isoforms in % total MHC.
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decrease mitochondrial function in isolated mitochondria
(26) and within heart tissue (27). This may also be the case
for skeletal muscle since the inducible NO synthase activity
has been found to increase in patients with CHF (10).
Second, oxidative capacity in muscle is influenced by de-
conditioning. Duscha et al. (11) emphasized the need to
compare patients with CHF to truly sedentary controls.
Such comparison allowed us to separate the deconditioning-
related changes (the mitochondrial intrinsic oxidative ca-
pacity) from the CHF-specific ones (the enzymatic changes
that are opposite to the ones expected from a shift to a faster
muscle phenotype) and to evidence similar intrinsic mito-
chondrial function in CHF and SED. This is in line with
the absence of skeletal muscle high-energy phosphate ab-
normalities in the only study comparing patients with CHF
to truly sedentary controls (28). This, again, favors the
hypothesis that CHF-specific metabolic abnormalities are
mostly of extramitochondrial origin. The functional coun-
terpart of these specific changes might be a decreased
high-energy phosphate transfer within the muscle cell
during exercise, as was already suggested to happen in
failing myocardium (20). Third, pharmacotherapy might
contribute to the differences between previous studies and
our findings. In experimental CHF in untreated animals (8),
we have recently described alterations in oxidative capacity
and mitochondrial regulation as well as a shift of the soleus
towards a more fast-glycolytic phenotype. In humans, Drex-
ler et al. (1), using ultrastructural morphometry, suggested
that the mitochondrial oxidative capacity was impaired in
CHF. Of note, only 26% of their patients took ACE
inhibitors, whereas all of ours did. It is now clearly estab-
lished that ACE inhibitors have a direct beneficial effect on
cardiac remodeling and energy metabolism (29); ACE
inhibitors have also been shown to protect the skeletal
muscle from structural alterations in models of CHF
(30,31), to correct abnormal MHC profiles in both animals
and patients (19,31) and to increase oxygen consumption
and skeletal muscle blood flow at exercise (32). Together
with their beneficial effects on exercise capacity, ACE
inhibitors also correct the energetic efficiency of the skeletal
muscle contractile machinery and protect against some
energy wasting mechanisms set by heart failure (31).
Mechanisms of exercise limitation in CHF. Our findings
suggest that in patients with CHF the maximal oxidative
capacity of the skeletal muscle mitochondria exceeds the
maximal exercise-induced muscle VO2. Thus, their abnor-
mal muscle metabolism should mainly result from mecha-
nisms upstream from the mitochondria. This is further
exemplified by the disruption of the normal relationship
between the parameters of mitochondrial function and of
exercise capacity (Fig. 4). The VO2max limitation involves
the succession of many steps controlling the delivery and
utilization of oxygen starting from lung capacity, cardiac
pump function, vascular content and resistance and ending
at the level of mitochondrial respiration. In normal animals
and humans, it is accepted that, during exercise involving a
large muscle mass, the absolute limit to VO2max lies in the O2
supply to the mitochondria rather than in its O2 demand and
that the relative importance of each step may vary depend-
ing on the degree of fitness (33–35). According to the
general concept of symmorphosis, there is no real excess
capacity for one step (except lung capacity) but rather a close
matching between functional and structural design at each
level (36). This suggests a sharing of the overall control of
oxygen consumption by each step. Indeed, skeletal muscle
(36) and heart tissue (37) utilize 80% to 90% of their
maximal mitochondrial VO2 at peak exercise. This is illus-
trated by the correlation we found between muscle oxidative
capacity and peak or VT VO2 in controls. The similar trend
in patients, although shifted towards the lower peak VO2
values, further suggests a restriction upward from the
mitochondria. Thus, pathology, in our case CHF, can
disrupt the normal structure and function relationship by
inducing limitations within the oxygen and substrate cas-
cade at levels that do not normally operate. Because Chom-
sky et al. (38) have shown that only a subset of patients with
severe CHF have a diminished cardiac output for a given
work rate, the abnormal convective O2 transport may also
result from a defect in blood flow redistribution, in the
microvasculature or in the diffusion from the capillary to the
cell (1,2,11). Although further studies are needed to explore
these hypotheses, the fact that the skeletal muscle intrinsic
mitochondrial function is preserved in patients with CHF
treated with ACE inhibitors indicates that further improve-
ments may be expected from therapeutic advances because
the microvascular functional alterations are more accessible
to interventions than intrinsic structural defects.
Conclusions. Having found similar intrinsic ADP-
stimulated respiratory features in the skeletal muscle of
patients with severe CHF and SED controls, we conclude
that, in patients with CHF adequately treated with long-
term ACE inhibitors, the exercise metabolic impairment of
the skeletal muscle results mostly from deconditioning and
factors upstream from the mitochondria that either decrease
the availability of oxygen and substrates or alter the mito-
chondrial environment during exercise. All these factors
might combine their deleterious effects to decrease exercise
capacity.
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